Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide (Q43180130)
scientific article published in December 2009
Language:
(P31) (Q13442814)
(P50) (Q108578052)
(Q89048137)
(P304) S26-34
(P478) 86 Suppl 1
(P577) Tuesday, December 1, 2009
(P921) (Q3025883)
(P1433) (Q15750054)
(P1476) "Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide" (language: en)
(P2093) Renate E van Genugten
(P2860) (Q35085591)
(Q33864120)
(Q56914456)
(Q36757992)
(Q36678584)
(Q24642503)
(Q51122414)
(Q34499706)
(Q68865252)
(Q29617302)
(Q24683764)
(Q58088431)
(Q44320631)
(Q28570314)
(Q45242112)
(Q28373115)
(Q72998037)
(Q37066877)
(Q45242151)
(Q51550359)
(Q42435174)
(Q51562589)
(Q77217124)
(Q43919658)
(Q45124469)
(Q46458866)
(Q46458868)
(Q33279692)
(Q28277510)
(Q46834147)
(Q24656644)
(Q46707421)
(Q51483637)
(Q42505421)
(Q27860882)
(Q47333592)
(Q37250791)
(Q28261998)
(Q24629441)
(Q46344895)
(Q24642412)
(Q44333619)
(Q28293505)
other details
description scientific article published in December 2009

External Links